Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Gains from Investment Securities (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Gains from Investment Securities for 4 consecutive years, with $300000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 2407.69% to $300000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $300000.0, a N/A change, with the full-year FY2025 number at $300000.0, changed N/A from a year prior.
  • Gains from Investment Securities was $300000.0 for Q4 2025 at Spruce Biosciences, up from -$13000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.4 million in Q4 2022 to a low of -$83000.0 in Q4 2023.
  • A 4-year average of $192111.1 and a median of $23000.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: tumbled 106.02% in 2023, then skyrocketed 2407.69% in 2025.
  • Spruce Biosciences' Gains from Investment Securities stood at $1.4 million in 2022, then crashed by 106.02% to -$83000.0 in 2023, then skyrocketed by 84.34% to -$13000.0 in 2024, then surged by 2407.69% to $300000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Gains from Investment Securities are $300000.0 (Q4 2025), -$13000.0 (Q4 2024), and $11000.0 (Q2 2024).